Wednesday, August 17, Mini-Review (2016) in Applied Microbiology and Biotechnology

Similar documents
MiniTEM. Designed for nanoparticle characterization

NutriVero Flex 10. Next-generation chemically defined serumfree, animal component free medium designed to support the growth of Vero cells

Professor Wei-Shou Hu Spring 2007 ChEn 5751

Outline. Upstream Processing: Development & Optimization

The Elite Provider. Cell & Gene. Therapy Manufacturing

Manufacturing Viral Gene Therapy Vectors: General Approaches and Challenges John T. Gray

Development from Bench to Clinic

Viral Products Expertise, Experience and Capability

cgmp Cell & Gene Therapy

Thermo Scientific Metabolic Pathway Design Process Cell culture media and process optimization approaches for optimal biotherapeutic production

Subject Index. chromatography step, 125-

Dr: RAWIA BADR Associate Professor of Microbiology&Immunology

Warm-Up. Describe how the Hershey-Chase experiment proved that DNA is the heritable molecule of genes.

Mammalian Expression Platform

Subject Index. See for options on how to legitimately share published articles.

Adenovirus upstream and downstream processing. Dr. Mats Lundgren GE Healthcare Life Sciences

CQAs for C&GT Products to Enable Comparability Assessment. Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline

Cultivation of sensitive cell lines - Improving bioreactor performance by dynamic membrane aeration

BalanCD HEK293 SYSTEM

Rapid selection of high yielding GS-CHO cell lines using the GS expression system in a protein-free, chemically defined, animal component-free process

Application Note USD3011. Influenza Virus Production with Adherent VERO Cells in PadReactor Mini Bioreactor

BalanCD HEK293 SYSTEM

Working Toward an Adenoviral Vector Testing Standard

Biosafety and the NIH Guidelines

Working Toward an Adenoviral Vector Testing Standard

The Zombies of the Scientific Community Viruses

Virus- infectious particle consisting of nucleic acid packaged in a protein coat.

Calvin College Biosafety Application

By two mechanisms: Mutation Genetic Recombination

Advanced Microbial Protein Expression

Use of the XCell ATF in the Manufacture of Suspension Lentiviral Vector

CONTINUOUS MANUFACTURING FOR BIOLOGICS & VACCINES

Biotechnology. Cloning. Transformation 2/4/ glue DNA

2.4 TYPES OF MICROBIAL CULTURE

Safe Operating Procedure

Application Note USD Microcarrier Mixing in PadReactor Mini Bioreactor

Application Note USD Pall SoloHill Animal Protein-Free Microcarriers for Dengue Virus Production

Chapter 13A: Viral Basics

Lecture Series 10 The Genetics of Viruses and Prokaryotes

Current Considerations on Chemistry, Manufacturing and Control of Cell Therapy Products (CTPs)

Titerless Infected-cells Preservation and Scale-up (TIPS) David J. Wasilko & S. Edward Lee Pfizer Global Research & Development Groton, CT

University of Delaware Department of Environmental Health & Safety Recombinant DNA Registration

icellis Bioreactors: Virus Production from Bench to Industrial Scale

Issues in production of viral gene transfer vectors. Stefan Kochanek Department of Gene Therapy Ulm University

Inspiring Advances in Bioprocessing. John Bonham-Carter March 14, 2017

Fujifilm Diosynth Biotechnologies Texas

SCIENTIFIC PROGRAMME CELL THERAPY AND CELL CHOICES IN THE SWISS TRANSPLANTATION PROGRAM- FROM THE LABORATORY TO CLINICAL RESEARCH AND USE

Modified atmosphere: enhancing insect cell cultures experimentation

Viral vectors Overcoming process. Dave Simpson PhD Process Development Manager

Overview Rentschler Biotechnologie

BARI CONSULTANTS S.W. 132 nd CT. W. Miami, Florida, , USA.

Mammalian and Plant Cell Culture Module 6 Introduction to bioprocessing and pharmabiotech Handout

Viral vector production for cell and gene therapy

Single use plastic settlers for clarifying cell culture broth, selective removal of dead cells and affinity capture of antibodies on protein A beads

Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology

1. Immunization. What is Immunization? 12/9/2016. Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology

Viruses and Prokaryotes

Antibiotic Resistance: Ampicillin and Gentamicin Bacterial Backbone: pfastbac (Invitrogen)

Outsourcing and Partnering for Commercial Grade Manufacturing Frank Tufaro, Ph.D.

Viral Clearance Studies

Multiple cloning site between CAG and wild type IRES:

Antibiotic Resistance: Ampicillin and Gentamicin Bacterial Backbone: pfastbac (Invitrogen)

DNA Cloning with Cloning Vectors

Recombinant or Synthetic Nucleic Acid Molecules

Vaccine Upstream Processing an overview

GVSU BIOSAFETY APPLICATION

BACTERIOPHAGES: STRUCTURE AND PROPERTIES OF BACTERIAL VIRUSES

Bioprocessing Challenges: High-Titer Mammalian-Based Cell Systems. Elements influencing the way Biologics may be manufactured /supplied in the future

Gene therapy. Findings by Alert

APPROACHES TO IMPROVING THE PERFORMANCE OF MAMMALIAN CELL CULTURES FOR PROTEIN PRODUCTION

MMG 301, Lec. 25 Mutations and Bacteriophage

Rachel Legmann, PhD ISCT, October 2, 2016 Memphis, TN

RECENT IMPROVEMENTS TO LONZA S GLUTAMINE SYNTHETASE (GS) GENE EXPRESSION SYSTEM. Dr Robert Gay

Lentiviral Vector Manufacturing Challenges and Solutions

Genetic tests are available for hundreds of disorders. DNA testing can pinpoint the exact genetic basis of a disorder.

Cellca Technology Platform

BIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE

Name Biol Group Number. ALE 11. The Genetics of Viruses, Control of Gene Expression, and Recombinant DNA Technology

Intensification of a Perfusion Platform using Single-use XCell ATF Systems

Genetics - Problem Drill 13: The Control of Gene Expression in Prokaryotes

In the biopharmaceutical industry,

Biosafety Level Host Range Propagation Comments

Yesterday s Picture UNIT 3E

Gene Technology classification of dealings involving self-inactivating, replication defective, retroviral vectors.

Biotechnology Unit: Viruses

Accelerated Development, Manufacturing and Monitoring of Viral Vectors Viral Vaccines Gene Therapy Oncolytic Viruses

COURSE OUTLINE. Biology 112 Microbiology

Innovative Bioreactor Systems for Enhancing Vero Cell growth

Chapter 18. Viral Genetics. AP Biology

Implementation of a Micro Bioreactor System for Platform Cell Culture Process Development at Cobra Biologics

Molecular Biology: Gene cloning

University of Lethbridge GUIDELINES FOR USE OF ADENO-ASSOCIATED VIRAL VECTORS (AAV VECTORS)

Hollow Fiber Bioreactors Product Line Introduction

G0202 pfbaavmcsbghpa MCS. Red type indicates unique restriction site. Plasmid Features:

Fig. 5.1(a) and Fig. 5.1(b), on page 3 of the insert, show some changes that take place in the fermenter over the first 6 days.

Integrity icellis. Single-Use Bioreactor for Process Intensification. The Source of Bioprocess Efficiency

Red type indicates unique restriction site. Antibiotic Resistance: Ampicillin and Gentamicin Bacterial Backbone: pfastbac (Invitrogen)

ABL Europe s GMP manufacturing facility for viral vector production

Applications involving the ViroCyt Virus Counter in the production of various recombinant proteins

Pharmaceutical. Manufacturing of viral vectors for gene therapy: part I. Upstream processing

Transcription:

Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production Wednesday, Mini-Review () in Applied Microbiology and Biotechnology Felipe Tapia, Daniel Vázquez-Ramírez, Yonne Genzel, Udo Reichl

Overview 1. Introduction 2. Adherent or suspension cells 3. Batch vs. fed-batch 4. Perfusion system 5. Multi-stage bioreactors 6. Outlook 7. References Seite 2

Introduction Virus replication (lytic cycles) 1. Attachment 2. Penetration 3. Replication 4. Assembly 5. Lysis & Release http://farm7.staticflickr.com/6238/6374709127_d2cc7784de.jpg Seite 3

Introduction DIPs - defective interfering particles spontaneously generated virus mutants The damage virus can still penetrate host cell, but require a fully virus particles existence of DIPs has been observed within nearly every class of both DNA and RNA viruses Problem by viral vaccine production => decrease maximum virus yield Seite 4

Introduction Key factor to increase virus production yields Cell concentration and metabolic/physiological status of the cells at time of infection Cell concentration defines the virus titer depening on status of cells Ratio of infectious particles to viable cells at the time of infection A too high number of virus particles per cell, can promote replication of defective interfering particles Residence time of virus particles within the bioreactor and time point of harvest The residence time affected the vaccine type live attenuated vaccines or inactivated vaccines depending on the application Seite 5

Suspension Cells Systems Hollow fiber bioreactor maximal growth is mainly limited by the total amount of nutrients and the accumulation of growth-inhibiting compounds Separate the viral particles http://cellab.eu/images/news/funktion_semipermeable_membran_hohlfaser_en.jpg Seite 6

Adherent Cells Systems Microcarrier in STR Maximum number of cells depends on the available growth surface Exchange the medium by sedimentation of carrier in STR http://images.fineartamerica.com/images-medium-large-5/1- microcarrier-beads-sem-david-m-phillips.jpg 1.8 x 10 6 cells/ml 1.1 x 10 7 cells/ml Seite 7

Batch vs. Fed-batch Batch: + ease of operation + process robustness Accumulation of by-products Fed-batch: + Potential to accomplish higher cell concentration + Avoid the accumulation of unwanted by-products through addition of medium Parapoxvirus ovis: 5.5 x 10 6 VP/Lh Parapoxvirus ovis: 1.1 x 10 8 VP/Lh Seite 8

Perfusion Systems + Potential to accomplish higher cell concentration + Avoid the accumulation of unwanted by-products through exchange of medium + Low footprint and high volumetric rates Disadvantages such as filter clog and limited scalability (spin filter) Adenovirus (HFK293): 7.8 x 10 9 IVP/ml http://www.magazine.emerck/magazine.entdecker.corp/en/images/bioreaktor_09_380_e_tcm1113_107016.jpg Seite 9

Perfusion Systems Different production profiles and kinetics Schematic representation of the perfusion-based high cell density (HCD) production of recombinant proteins (a) and viruses (b) Seite 10

Multi-stage bioreactor + steady-state operation + high volumetric efficiency + lower plant turndown that enhance process yield + two-stage STR bioreactor for continuous influenza A virus production large volumes of media consumed or the extended production time by HCD production Influenza A/PR/8/34 (AGE1-CR.plX): 7.0 x 10 9 IVP/ml Seite 11

Multi-stage bioreactor Passage effect Increase the amount of non-occluded virus particles for up to 25 day continuous mode Three stage bioreactor enhance the passage effect with higher virus passage number an earlier drop in virus yield passage effect induced by DIPs Seite 12

Outlook apply knowledge for process intensification and other cell culture products automation technologies (on-line monitoring of metabolites) availability of technologies for establishing HCD under cgmp conditions continuous processes also an interesting option to batch production Limiting factor by the accumulation of DIPs => reduced product titer HCD cultivation using fed-batch or perfusion strategies, studies currently show cell concentration exceeding 10 8 cells/ml Seite 13

References Cortin V, Thibault J, Jacob D, Garnier A (2004) High-titer adenovirus vector production in 293S cell perfusion culture. Biotechnol Prog 20(3):858 863. Bock A, Schulze-Horsel J, Schwarzer J, Rapp E, Genzel Y, Reichl U (2011) High-density microcarrier cell cultures for influenza virus production. Biotechnol Prog 27(1):241 250. Pohlscheidt M, Langer U, Minuth T, Bodeker B, Apeler H, Horlein HD, Paulsen D, Rubsamen-Waigmann H, Henzler HJ, Reichl U (2008) Development and optimisation of a procedure for the production of Parapoxvirus ovis by large-scale microcarrier cell culture in a nonanimal, non-human and non-plant-derived medium. Vaccine 26(12): 1552 1565. Hu YC, Wang MY, Bentley WE (1997) A tubular segmented-flow bioreactor for the infection of insect cells with recombinant baculovirus. Cytotechnology 24(2):143 152. Castilho L, Moraes A, Augusto E, Butler M (2008) Animal cell technology: from biopharmaceuticals to gene therapy. Taylor & Francis Group, New York; Abingdon England Seite 14

Thank you for your attention. Any questions.? Seite 15